You're on Retatrutide and Want a GH Peptide. Here's Which One to Choose.

If you're on retatrutide and you want to add a GH peptide, the question you're probably asking is some version of this: "Tesamorelin specifically targets visceral fat — that's what I want to lose. Wouldn't that be better than CJC-1295?"

It's a logical question. And the answer is less obvious than most forum posts make it.

What retatrutide is already doing to your visceral fat

Before comparing the two GH peptides, you need to understand what's already happening in your body on retatrutide.

Retatrutide is a triple agonist — it hits GLP-1, GIP, and glucagon receptors simultaneously. The glucagon arm is the piece that matters here: it drives hepatic fat oxidation and thermogenesis in a way the earlier GLP-1 drugs simply cannot. In the Phase 2a MASLD trial, retatrutide reduced liver fat by up to 86% over 48 weeks, and visceral adipose tissue loss accompanies that metabolic shift [RCT — Sanyal et al., *Nature Medicine* 2024, PMID 38858523]. The magnitude of visceral-fat mobilization on retatrutide is unlike anything else in outpatient medicine.

So the first question to ask before adding a visceral-fat-specialist peptide is: do you actually have a visceral-fat problem that retatrutide isn't already solving?

For most people on retatrutide — especially at 4 mg and above where the glucagon receptor fully activates — the answer is no. Retatrutide is the visceral-fat tool. What you need from a GH peptide is something different.

What you actually need from a GH peptide on retatrutide

Retatrutide creates a significant caloric deficit. That's what drives the weight loss. And in a caloric deficit, your body has to decide what to break down for fuel — fat, muscle, or both. Lean mass loss on GLP-1 class drugs runs roughly 25–40% of total weight lost without intentional countermeasures [HUMAN — STEP-1 and SURMOUNT-1 body composition substudies].

The GH axis is one of the countermeasures. Growth hormone is the signal that tells your body to spare muscle during a deficit — it shifts substrate utilization toward fat and away from protein. A GH secretagogue like CJC-1295 amplifies the natural nocturnal GH pulses that drive this lean-mass protection.

That's the job. Not "target my love handles additionally" — retatrutide is already doing that. The job is: tell your body to keep the muscle while Reta melts the fat.

Why CJC-1295 is the right tool for that job

CJC-1295 is a GHRH analog — it mimics the hypothalamic signal that triggers GH pulses from your pituitary. It works on an entirely different receptor system than retatrutide (GHRH receptor vs. GLP-1/GIP/glucagon receptors). There is no pharmacological overlap between the two, which means there's no theoretical interaction concern.

The practical effect: more frequent, larger GH pulses → better lean-mass preservation during the retatrutide-driven deficit → better body composition at your endpoint weight.

Most people run CJC-1295 with ipamorelin, because they work on two separate pituitary levers. CJC-1295 mimics the GHRH trigger; ipamorelin mimics a separate ghrelin-pathway pulse amplifier. Together they produce a more complete GH response than either does alone. The pre-blended CJC-1295/ipamorelin vial from Alyve or US Pure Peptides is the convenient way to run the combination.

Dosing: most protocols use 100–200 mcg of each, subcutaneous, before bed on an empty stomach. This catches and amplifies the natural nocturnal GH pulse rather than competing with it. Keep this entirely separate from your weekly retatrutide injection.

Why tesamorelin is more complicated on retatrutide

Tesamorelin is a more potent GHRH analog than CJC-1295 — it drives stronger and more sustained IGF-1 elevation and has Phase 3 human trial data showing it specifically reduces visceral fat by 15–18% in its studied population.

In isolation, it's a remarkable peptide. The complication is what happens when you put it on top of retatrutide.

The combination has zero published human studies. No pharmacokinetic data, no interaction profile, no safety record in combination. The mechanisms point in different directions: tesamorelin drives a sustained anabolic/GH-axis effect; retatrutide's glucagon arm drives a catabolic/thermogenic effect. The net metabolic outcome of running both simultaneously is genuinely unknown.

The more specific concern is IGF-1. Tesamorelin drives sustained IGF-1 elevation, and IGF-1 is a mitogen — its biological job is to signal cells to grow and divide. Population-level epidemiology shows associations between upper-tertile IGF-1 and elevated risk for certain cancers [HUMAN — Renehan et al. 2004, *Lancet*, PMID 15110491]. That's a correlation in observational data, not a proven causal effect from tesamorelin — but the direction the biology points is worth taking seriously. Adding a second sustained GH-axis stimulator on top of an already powerful metabolic drug pushes IGF-1 higher and longer with no data on what that means over a 6-12 month protocol.

The tesamorelin wiki covers this in depth, including the three specific reasons the stack warrants caution (compounded IGF-1 concern, mechanism mismatch, and double extrapolation from the studied population). The short version: it's not that tesamorelin with retatrutide is proven dangerous — it's that you'd be pioneering an unstudied combination with a mechanism that points toward a real concern, for a visceral-fat goal that retatrutide is already handling. That's not a trade worth making for most people.

The stack that works

On retatrutide, the GH-axis support that makes sense:

CJC-1295 + Ipamorelin — 100–200 mcg each, subcutaneous, before bed, 5 days on / 2 off or daily. Both are available as a pre-blended vial at Alyve Peptides — use code OHM-15 for 15% off (buying 3 vials gets you over 30% off retail). Also available individually at US Pure Peptides with code OHM20 for 20% off.

Alongside the peptide work: protein at 1.6–2.4 g/kg body weight/day and resistance training 3+ sessions per week are not optional — they're what the GH signal has to work with. A GH pulse with no mechanical stimulus to respond to doesn't build muscle; it just circulates. The peptide amplifies the training response; the training provides the signal.

The bottom line

If you're on retatrutide and want to add a GH peptide for visceral fat and body composition: CJC-1295 with ipamorelin is the answer. It addresses the actual gap — lean muscle preservation during a retatrutide-driven deficit — without the unstudied-combination and compounded-IGF-1 concerns of tesamorelin.

Tesamorelin is a genuinely powerful peptide that earns serious consideration in other contexts. On retatrutide specifically, the combination hasn't been studied, and the mechanism doesn't give you a clean reason to take that bet when the safer option does the job you actually need done.

CJC-1295/Ipamorelin blend is available at Alyve Peptides — use code OHM-15 for 15% off, or buy 3 vials for over 30% off retail. CJC-1295 and ipamorelin are also available individually at US Pure Peptides — use code OHM20 for 20% off. Retatrutide is available at Alyve — Alyve-only for Reta per OHM's verified-vendor routing.